Vedanta biosciences publishes phase 1a/1b results for lead program ve303 in cell host & microbe and highlights planned presentations of phase 2 ve303 results

Cambridge, mass.--(business wire)--vedanta biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication in the journal cell host & microbe of the results from a phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of ve303 in healthy adults. ve303 is a potential first-in-class defined bacterial consortium candidate for the prevention of recurrent clostridi
PRTC Ratings Summary
PRTC Quant Ranking